Safety and Immunogenicity Trial of High-Dose Quadrivalent Influenza Vaccine Administered by Intramuscular Route in Subjects Aged 65 Years and Older
Phase of Trial: Phase II
Latest Information Update: 28 Apr 2017
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors sanofi pasteur
- 17 Feb 2017 Status changed from active, no longer recruiting to completed.
- 07 Jul 2016 Planned End Date changed from 1 Sep 2016 to 1 Oct 2016.
- 29 Apr 2016 Planned End Date changed from 1 Jun 2016 to 1 Sep 2016.